Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$5.37 - $7.07 $117,151 - $154,239
-21,816 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $46,430 - $62,941
8,381 Added 62.38%
21,816 $135,000
Q1 2021

May 17, 2021

SELL
$5.12 - $8.48 $23,552 - $39,008
-4,600 Reduced 25.51%
13,435 $107,000
Q4 2020

Feb 16, 2021

SELL
$3.16 - $7.03 $19,481 - $43,339
-6,165 Reduced 25.48%
18,035 $105,000
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $10,432 - $15,136
3,200 Added 15.24%
24,200 $82,000
Q2 2020

Aug 14, 2020

SELL
$1.58 - $4.63 $20,066 - $58,801
-12,700 Reduced 37.69%
21,000 $97,000
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $27,000 - $36,840
12,000 Added 55.3%
33,700 $92,000
Q3 2019

Nov 14, 2019

BUY
$2.67 - $3.65 $57,939 - $79,205
21,700 New
21,700 $64,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.